{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:30:46Z","timestamp":1785828646830,"version":"3.56.0"},"reference-count":77,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T00:00:00Z","timestamp":1364169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research Pt B"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:p>Interleukin\u20106 (IL\u20106) is involved in the pathogenesis of multiple disorders, including juvenile autoimmune diseases. IL\u20106 participates in a broad spectrum of physiological events, and the IL\u20106 receptor (IL\u20106R) is widely distributed across multiple organs. The interrelationship of development phases in juveniles together with organs involved in IL\u20106 signaling called for evaluations of anti\u2013IL\u20106R antibody induced effects in a juvenile mouse model to assess the safety of such an approach in human juvenile arthritis. Here we show that naive mice in which IL\u20106 signals have been transiently blocked during the juvenile period develop normally. The fatal immunogenic reactions recorded earlier by repeated administration of the chosen rat anti\u2010mouse IL\u20106R antibody, MR16\u20101, to mice were avoided successfully by application of a high loading dose followed by lower maintenance doses, with the support of modeling data. The high loading\u2010dose regimen enabled us to conduct assessments without any major interference due to immunogenicity. Transient and complete inhibition of IL\u20106 signals from postnatal days 22 to 79 in mice exhibited no biologically important changes in sexual maturation or development of immune and skeletal systems. Although tendencies toward reductions of peripheral blood T\u2010cell counts were observed, normal levels of antigen\u2010specific IgG\/IgM antibody productions indicating sufficient immunological functions were confirmed. Our results demonstrate that blockage of IL\u20106R by the neutralizing antibody does not affect juvenile development. This may be in part due to the generation or existence of compensatory pathways in the whole body system.<\/jats:p>","DOI":"10.1002\/bdrb.21053","type":"journal-article","created":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T18:56:03Z","timestamp":1364237763000},"page":"170-182","source":"Crossref","is-referenced-by-count":7,"title":["The Effects of Interleukin\u20106 Signal Blockade on Immune System, Reproductive and Skeletal Development in Juvenile Mice"],"prefix":"10.1002","volume":"98","author":[{"given":"Takayuki","family":"Sakurai","sequence":"first","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takai","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"B\u00fcrgin","sequence":"additional","affiliation":[{"name":"Non\u2010Clinical Safety Pharma Research and Early Development F. Hoffmann\u2010La Roche Ltd.  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Shioda","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Amano","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Peter","family":"Grimm","sequence":"additional","affiliation":[{"name":"Non\u2010Clinical Safety Pharma Research and Early Development F. Hoffmann\u2010La Roche Ltd.  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang F.","family":"Richter","sequence":"additional","affiliation":[{"name":"Non\u2010Clinical Safety Pharma Research and Early Development F. Hoffmann\u2010La Roche Ltd.  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Chiba","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Primary Lifecycle Management Department Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Non\u2010Clinical Safety Pharma Research and Early Development F. Hoffmann\u2010La Roche Ltd.  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(03)00233-3"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/75068"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0531.2008.01318.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb06659.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.12.8338"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2003.11.022"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709205105"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)55079-1"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1406"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00358-3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/82763"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.8.5290"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119207"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000064757"},{"issue":"7","key":"e_1_2_7_16_1","first-page":"1403","article-title":"Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis","volume":"24","author":"De Benedetti F","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22175"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13799"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(02)00210-9"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081571"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"key":"e_1_2_7_22_1","unstructured":"EMA.2008. Guideline on the need for non\u2010clinical testing in juvenile animals on human pharmaceuticals for paediatric indications.European Medicines Agency (EMA) Committee for Medicinal Products for human use (CHMP)."},{"key":"e_1_2_7_23_1","unstructured":"FDA.2006.Guidance for industry. Nonclinical Safety Evaluation of Pediatric Drug Products.United States Food and Drug Administration (FDA)."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009350623"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(95)03475-M"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.00108s3463"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00151-0"},{"key":"e_1_2_7_28_1","unstructured":"ICH.2009.International Conference on Harmonization M3(R2): guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals."},{"key":"e_1_2_7_29_1","unstructured":"ICH.2012.International Conference on Harmonization M3(R2): guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Questions & Answers (R2)."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.6.3463"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(02)00013-3"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2008.10.007"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.6.935"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.151.2.389"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/368339a0"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070801"},{"issue":"3","key":"e_1_2_7_37_1","first-page":"R798","article-title":"Role of interleukin 6 in fever in rats","volume":"258","author":"LeMay LG","year":"1990","journal-title":"Am J Physiol"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.7.3031"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23291"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.3.1253"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.79.2.633"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/15476910490894904"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901929"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501794102"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(02)00201-8"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20305"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.8.3092"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.2.332"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2009.05.002"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.12.007"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01003.x"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.12.1551"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(02)00202-X"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901843"},{"key":"e_1_2_7_55_1","unstructured":"PMDA.2012.Guideline on the Nonclinical Safety Study in Juvenile Animals for Pediatric Drugs.Pharmaceuticals and Medical Devices Agency (PMDA)."},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06368.x"},{"issue":"2","key":"e_1_2_7_57_1","first-page":"161","article-title":"Interleukin\u20106 expression during normal maturation of the mouse testis","volume":"16","author":"Potashnik H","year":"2005","journal-title":"Eur Cytokine Netw"},{"issue":"11","key":"e_1_2_7_58_1","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.4049\/jimmunol.150.11.4844","article-title":"Response of human NK cells to IL\u20106 alterations of the cell surface phenotype, adhesion to fibronectin and laminin, and tumor necrosis factor\u2010alpha\/beta secretion","volume":"150","author":"Rabinowich H","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0063"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80334-9"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.2741\/1690"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21019"},{"issue":"10","key":"e_1_2_7_64_1","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.4049\/jimmunol.160.10.4841","article-title":"Partial TCR signals delivered by FcR\u2010nonbinding anti\u2010CD3 monoclonal antibodies differentially regulate individual Th subsets","volume":"160","author":"Smith JA","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.8.1413"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.19.7547"},{"issue":"10","key":"e_1_2_7_67_1","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/oxfordjournals.humrep.a135793","article-title":"Progressive rise in the expression of interleukin\u20106 in human endometrium during menstrual cycle is initiated during the implantation window","volume":"10","author":"Tabibzadeh S","year":"1995","journal-title":"Hum Reprod"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.45736-0"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1089\/107999099312948"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.1.108.108"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.4.1417"},{"issue":"5","key":"e_1_2_7_72_1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood.V84.5.1434.1434","article-title":"Effects of recombinant human interleukin\u20106 in cancer patients: a phase I\u2010II study","volume":"84","author":"Gameren MM","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)58628-2"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/gye.16.2.121.129"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60296-5"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1500-8"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.10012"}],"container-title":["Birth Defects Research Part B: Developmental and Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdrb.21053","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdrb.21053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T23:46:10Z","timestamp":1696549570000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdrb.21053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,25]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1002\/bdrb.21053"],"URL":"https:\/\/doi.org\/10.1002\/bdrb.21053","archive":["Portico"],"relation":{},"ISSN":["1542-9733","1542-9741"],"issn-type":[{"value":"1542-9733","type":"print"},{"value":"1542-9741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,25]]}}}